
Photo by Tani Scanni

November
5-7
2026

Villa Romanazzi
Carducci

Bari (Italy)

INTERNATIONAL
CONGRESS

Multiple Myeloma and Related Malignancies

8th Edition 2026

Presidents and Scientific Coordinators
Prof. Angelo Vacca
Prof. Roberto Ria
Prof. Antonio Giovanni Solimando

UNDER THE AUSPICES OF

UNIVERSITÀ DEGLI STUDI DI BARI ALDO MORO

SIMI
SOCIETÀ ITALIANA DI MEDICINA INTERNA
Patrocinio

SIE
Società Italiana di Ematologia

SIES
Società Italiana Ematologia Sperimentale

REGIONE PUGLIA
Patrocinio del Presidente della Giunta Regionale, concesso con Decreto n°576 del 20/10/2026

DARE
DIGITAL LIFELONG PREVENTION

SCIENTIFIC SECRETARIAT

Alessandro Andriano
Giulia de Martino
Vanessa Desantis
Antonio Vacca

PRESENTATION

In the last 20 years remarkable advancements in the understanding of the pathophysiology of Multiple Myeloma and related malignancies have paved the way to the identification and the subsequent adoption of new effective and safe therapies. Following the 7th edition which was held on November 7 - 9th, 2024, the time has come for a thorough biological and clinical update. Like in the previous editions, we aim to provide hematologists, oncologists, internists, radiologists, and other medical specialists as well as young researchers, residents, doctoral and undergraduate students with an invaluable opportunity to deepen and update their knowledge on the already acquired and emerging developments in the biology and treatment of Multiple Myeloma and related malignancies.

A number of internationally renowned speakers have been invited to deliver *state-of-the-art* lectures on cutting edge topics. These will include genetic and epigenetic features of myeloma biology, molecular and biological mechanisms of disease progression, new prognostic markers and novel approaches to assess the response to therapy, new single or combined therapeutic molecules specifically targeting tumor cells and/or their microenvironment. Autologous and allogeneic stem cell transplantation, bispecific monoclonal antibodies, and CAR-T cells will also be the object of intensive scrutiny. Finally, supportive therapy, emerging toxicity, and infectious complications will be discussed in their many facets.

We are confident that at the end of the meeting all of us will be enriched with fresh stimuli and renewed enthusiasm, with the deep awareness that the enduring challenges posed by Multiple Myeloma and cognate tumors may now be approached with more rational and more effective achievements.

Angelo Vacca, Roberto Ria and Antonio Giovanni Solimando

FACULTY

Albano Francesco	Italy
Amodio Nicola	Italy
Bahlis Nizar	Canada
Barila' Gregorio	Italy
Beilhack Andreas	Germany
Belotti Angelo	Italy
Bergsagel Leif	USA
Botta Cirino	Italy
Bringhen Sara	Italy
Bruno Benedetto	Italy
Buda Gabriele	Italy
Cea Michele	Italy
Cenci Simone	Italy
Cerchione Claudio	Italy
Chesi Marta	USA
Cupedo Thomas	Netherlands
Da Via' Matteo Claudio	Italy
D'Agostino Mattia	Italy
De Novellis Danilo	Italy
Derudas Daniele	Italy
Desantis Vanessa	Italy
Einsele Hermann	Germany
Furlan Anna	Italy
Galli Monica	Italy
Gay Francesca	Italy
Gulla' Annamaria	Italy
Jaccard Arnaud	France
Jolles Stephen	UK
Lazzaroni Francesca	Italy
Leleu Xavier	France
Liberatore Carmine	Italy
Mangiacavalli Silvia	Italy
Marchesini Matteo	Italy
Martello Marina	Italy
Maura Francesco	USA
Mele Giuseppe	Italy
Milani Paolo	Italy
Montefusco Vittorio	Italy
Morelli Eugenio	Italy
Mosquera Orgueira Adrián	Spain
Munshi Nikhil	USA
Musto Pellegrino	Italy
Neri Paola	Canada
Oskarsson Jon Thorir	Iceland
Piazza Francesco	Italy
Quinto Angela Maria	Italy
Ria Roberto	Italy
Richardson Paul	USA
Roccaro Aldo	Italy
Rossini Bernardo	Italy
Sánchez - Ramon Silvia	Spain
Solimando Antonio G.	Italy
Storti Paola	Italy
Tabares Gaviria Paula	Germany
Tarantini Giuseppe	Italy
Terragna Carolina	Italy
Vacca Angelo	Italy
Waldschmidt Johannes	Germany
Willenbacher Ella	Austria
Willenbacher Wolfgang	Austria
Yong Kwee	UK
Zamagni Elena	Italy
Zambello Renato	Italy

THURSDAY, **NOVEMBER 5, 2026**

13.30 - 14.15	Registration of participants
14.15 - 14.30	Welcome speech and orientation **Angelo Vacca, Roberto Ria, Antonio Giovanni Solimando**
14.30 - 15.00	Opening Lecture
Chairperson:	**Roberto Ria**
	The Bone Marrow Microenvironment: A History of Over 30 Years **Angelo Vacca**
15.00 - 16.40	***Workshop 1*** **Biology: Genomic, Epigenetic and Proteomic of Multiple Myeloma and Precursors**
Chairpersons:	**Michele Cea, Francesca Lazzaroni, Eugenio Morelli**
15.00 - 15.25	Genetics of Multiple Myeloma: From Founder Events to Dominant Clones **Leif Bergsagel**
15.25 - 15.50	Stromal–Immune Interactions Orchestrate Disease Adaptation **Thomas Cupedo**
15.50 - 16.15	Metabolic Vulnerabilities of Multiple Myeloma **Simone Cenci**
16.15 - 16.40	Multiple Myeloma Models: the Paradigm of Immunocompetent Murine Approaches **Marta Chesi**
16.40 - 17.00	*Coffee break*
17.00 - 19.30	***Workshop 2*** **Prognostic Stratification of Plasma Cell Dyscrasias**
Chairpersons:	**Claudio Cerchione, Carmine Liberatore**
17.00 - 17.25	Development and Validation of Novel Machine Learning- and AI-Based Approaches **Adrián Mosquera Orgueira**
17.25 - 17.50	MGUS Screening in Practice: From Early Detection to Risk-Adapted Decisions **Jon Thorir Oskarsson**
17.50 - 18.15	Smoldering Myeloma: When Risk Becomes Disease **Francesco Maura**
18.15 - 18.40	Modern Risk Stratification in Newly Diagnosed Multiple Myeloma **Mattia D'Agostino**
18.40 - 19.05	Functional High Risk **Claudio Cerchione**
19.05 - 19.30	Primary Plasma Cell Leukemia **Pellegrino Musto**

FRIDAY, **NOVEMBER 6, 2026**

08.30 - 10.35 ***Workshop 3***
First Line Therapy

Chairpersons: **Sara Bringhen, Gabriele Buda, Danilo De Novellis**

08.30 - 08.55 Evolving Treatment Pathways for Transplant-Eligible Multiple Myeloma
Francesca Gay

08.55 - 09.20 Maintenance Therapy in Multiple Myeloma: Patient Selection and Treatment Duration
Elena Zamagni

09.20 - 09.45 Individualizing Frontline Treatment in Transplant-Eligible Multiple Myeloma
Xavier Leleu

09.45 - 10.10 Optimizing Quadruplet-Based First-Line Therapy in Non-Transplant-Eligible Multiple Myeloma (CEPHEUS and IMROZ Legacy)
Vittorio Montefusco

10.10 - 10.35 When Cell Death Becomes Immunogenic: Predictors and Modifiers of Anti-Tumor Immunity
Annamaria Gullà

10.35 - 11.00 *Coffee break*

11.00 - 12.40 ***Workshop 4***
Clinical Features: Focus on Secondary Immunodeficiency and Clinically Meaningful Modern Adverse Events

Chairpersons: **Anna Furlan, Giuseppe Tarantini, Ella Willenbacher**

11.00 - 11.25 Secondary Immunodeficiency in Multiple Myeloma
Stephen Jolles

11.25 - 11.50 Early Red Flags and Long-Term Adverse Event Management
Roberto Ria

11.50 - 12.15 Infections After Current Treatments: The Role of Registries
Wolfgang Willenbacher

12.15 - 12.40 CHIP and Secondary Neoplasm
Johannes Waldschmidt

12.40 - 14.00 *Lunch*

FRIDAY, **NOVEMBER 6, 2026**

14.00 - 14.30 **Keynote Lecture**

Chairperson: **Antonio Giovanni Solimando**

Disease Biology Guiding Therapy
Nikhil Munshi

14.30 - 16.35 ***Workshop 5***
Evaluation of Response and Role of Minimal Residual Disease

Chairpersons: **Francesco Albano, Bernardo Rossini, Renato Zambello**

14.30 - 14.55 NGS for Risk Assessment at Diagnosis and MRD Measurement
Carolina Terragna

14.55 - 15.20 NGF for Risk Assessment at Diagnosis and MRD Measurement
Paula Tabares Gaviria

15.20 - 15.45 Imaging to Response Evaluation
Angelo Belotti

15.45 - 16.10 MRD Spotlight - Measuring, Researching, and Directing Validated and Future Avenues
Cirino Botta

16.10 - 16.35 Circulating Myeloma: The Emerging Role of cfDNA and CTCs
Marina Martello

16.35 - 16.50 *Coffee break*

16.50 - 18.30 ***Workshop 6***
Relapsed/Refractory Myeloma

Chairpersons: **Benedetto Bruno, Silvia Mangiacavalli, Giuseppe Mele**

16.50 - 17.15 How to Select the Appropriate Therapy for RRMM in the Real-World Setting
Kwee Yong

17.15 - 17.40 Resistance to Anti-BCMA
Paola Neri

17.40 - 18.05 Resistance to Anti-GPRC5D
Nizar Bahlis

18.05 - 18.30 Future T-Cell Based Approaches in Myeloma
Hermann Einsele

18.30 - 19.20 **Poster session**
Selected poster presentation

Chairpersons: **Nicola Amodio, Matteo Marchesini, Paola Storti**

SATURDAY, **NOVEMBER 7, 2026**

08.15 - 08.30 Best poster presentation

Chairpersons: **Vanessa Desantis, Antonio Giovanni Solimando**

08.30 - 10.10 ***Workshop 7***
Latest Therapeutic Options: Pro and Contra

Chairpersons: **Claudio Cerchione, Monica Galli, Antonio Giovanni Solimando**

08.30 - 08.55 Ten Years of Carfilzomib in Multiple Myeloma: Optimizing its Role from Relapsed Disease to Early-Line Positioning and Bridging Approaches
Gregorio Barilà

08.55 - 09.20 The Paradigm of Extramedullary Multiple Myeloma: from Resistance to Identification of Novel Therapeutic Targets and Strategies
Matteo Claudio Da Vià

09.20 - 09.45 Novel Immunotherapeutic Approaches Beyond CAR-T and BiTEs
Andreas Beilhack

09.45 - 10.10 Next-Generation Myeloma Therapies Outside T-Cell-Engaging Platforms
Paul Richardson

10.10 - 10.35 *Coffee break*

10.35 - 12.15 ***Workshop 8***
Special conditions

Chairpersons: **Daniele Derudas, Angela Maria Quinto, Aldo Roccaro**

10.35 - 11.00 POEMS Syndrome and Related Conditions
Arnaud Jaccard

11.00 - 11.25 Why Secondary Infection Cannot be a Secondary Consideration
Silvia Sánchez-Ramón

11.25 - 11.50 Heart and Neuropathy: the Dual Burden of AL vs ATTR Amyloidosis
Paolo Milani

11.50 - 12.15 Waldenstrom Macroglobulinemia: Novel Insights on Biology and Therapy
Francesco Piazza

12.15 - 12.40 Closing Remarks
Angelo Vacca, Roberto Ria, Antonio Giovanni Solimando

Congress Closure and CME questionnaire

GENERAL INFORMATION

VENUE
Villa Romanazzi Carducci
Via Giuseppe Capruzzi 326
Bari (Italy)

REGISTRATION
Attendance is free of charge.
Registration can be made through the website www.meeting-planner.it (select the congress in the section "Calendario eventi" - Eventi).

CONTINUING MEDICAL EDUCATION (CME) - event n. 493503
This Congress has been assigned **n. 11,9** credits.
This training event is for Medical specialists in the following areas:
Internal Medicine, Allergology and Clinical Immunology, Hematology, Oncology, Emergency Medicine, Geriatrics, Anatomic Pathology, Infectious diseases, Radiology, Radiotherapy, Orthopedics and traumatology, Clinical Biochemistry, Pharmacology and Clinical Toxicology, Medical Genetics Laboratory, Clinical Pathology, General Practice, Hospital Medical Management and General Practice and Pharmacists.
CME credits can be claimed and your CME certificate issued only if you:
• have attended the entire training event
• have passed the CME assessment survey (a score of 75% or higher must be attained)
There can be no exceptions to these mandatory steps.
Attendants are also required not to exceed acquiring over 1/3 of their credits for the three-year period (2026- 2028) by recruitment invitation.

AIMS OF THE TRAINING PROCESS
Guidelines, Protocols, Procedures (2)

LANGUAGE
The official language is English.

PROVIDER AND ORGANIZING SECRETARIAT

MP S.r.l. - Società a socio unico e soggetta all'attività di direzione e coordinamento di Meduspace S.p.A. Società Benefit
CME Provider n° 2516
Via Vincenzo Sassanelli, 56 – 70124 Bari
TEL. +39 080.9905359 – +39 080.9905360
E-mail: info@meeting-planner.it – www.meeting-planner.it

SISTEMA DI GESTIONE QUALITÀ CERTIFICATO CQY CERTIQUALITY UNI EN ISO 9001:2015
SISTEMA DI GESTIONE PARITÀ DI GENERE CQY CERTIQUALITY UNI/PDR 125:2022

NOTES

With the unconditional support of































